Cowen reiterated their hold rating on shares of Bruker (NASDAQ:BRKR) in a research note issued to investors on Thursday. Cowen currently has a $35.00 price objective on the medical research company’s stock.

A number of other research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Bruker from a buy rating to a hold rating in a research report on Friday, November 10th. Citigroup raised their target price on shares of Bruker from $29.00 to $34.00 and gave the company a neutral rating in a research report on Friday, November 3rd. Bank of America raised shares of Bruker from an underperform rating to a neutral rating and set a $34.00 target price for the company in a research report on Friday, November 3rd. JPMorgan Chase & Co. raised shares of Bruker from an underweight rating to a neutral rating and set a $28.00 target price for the company in a research report on Friday, November 3rd. Finally, Goldman Sachs Group reaffirmed a sell rating and issued a $24.00 target price on shares of Bruker in a research report on Tuesday, September 26th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $30.58.

Bruker (NASDAQ:BRKR) opened at $34.08 on Thursday. The firm has a market cap of $5,312.47, a price-to-earnings ratio of 36.26, a P/E/G ratio of 2.89 and a beta of 1.12. Bruker has a 12-month low of $21.10 and a 12-month high of $36.53. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60.

Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.02. The business had revenue of $435.60 million during the quarter, compared to the consensus estimate of $415.45 million. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.32 earnings per share. equities analysts forecast that Bruker will post 1.19 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, December 22nd. Shareholders of record on Monday, December 4th were paid a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a yield of 0.47%. The ex-dividend date was Friday, December 1st. Bruker’s dividend payout ratio is currently 17.02%.

A number of hedge funds have recently made changes to their positions in the business. Acrospire Investment Management LLC lifted its stake in shares of Bruker by 496.1% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock worth $110,000 after buying an additional 3,185 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Bruker during the 2nd quarter worth about $111,000. Zions Bancorporation acquired a new stake in shares of Bruker during the 3rd quarter worth about $119,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Bruker by 11.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock worth $133,000 after buying an additional 467 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Bruker by 7.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock worth $144,000 after buying an additional 331 shares during the last quarter. Hedge funds and other institutional investors own 65.60% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Bruker (BRKR) Earns “Hold” Rating from Cowen” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://theolympiareport.com/2017/12/25/bruker-brkr-earns-hold-rating-from-cowen.html.

About Bruker

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with Analyst Ratings Network's FREE daily email newsletter.